Ibuprofen Altan (Ibuprofen)

Ibuprofen blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, preventing the formation of prostaglandins that mediate pain, fever, and inflammation. By lowering prostaglandin levels, it reduces peripheral sensitisation, lowers the hypothalamic temperature set‑point, and limits inflammatory swelling.

The appropriate dose of Ibuprofen Altan is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other clinical factors. Specific dosing regimens are not disclosed publicly and should follow the prescriber’s order.

Safety of intravenous ibuprofen during pregnancy has not been established, and it is generally avoided, especially in the third trimester. Breastfeeding mothers should consult their healthcare provider, as ibuprofen can be excreted in milk and may affect the infant.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Ibuprofen Altan offers a well‑known safety profile and is often compared with IV ketorolac. While both provide potent analgesia, ibuprofen has a slightly longer half‑life and may be preferred when a broader anti‑inflammatory effect is desired, whereas ketorolac is typically limited to short‑term use because of higher renal and bleeding risk.

The product should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperatures. Once opened, use according to the manufacturer’s aseptic guidelines and discard any remaining solution after the recommended in‑use period.

Ibuprofen Altan is given by intravenous infusion. The solution is diluted in an appropriate compatible fluid and administered over the time period prescribed by the clinician, typically ranging from a few minutes to an hour, depending on the dose and patient tolerance.

Serious adverse events include gastrointestinal bleeding, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, acute renal failure, cardiovascular thrombotic events (e.g., myocardial infarction or stroke) and hepatic necrosis. Immediate medical attention is required if any of these occur.

Patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulceration, uncontrolled bleeding disorders, severe renal or hepatic impairment, and those in the third trimester of pregnancy should avoid this medication. Use should also be cautious in patients with cardiovascular disease.